Treatment with Secukinumab shows no Evidence for an increased Incidence of Mycobacterium tuberculosis Infections: Results from in vitro, in vivo and clinical Investigations
XX
BSO - Titre
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
